Latanoprostene Bunod

CAS 860005-21-6 6 current recordsSmall Molecule

Who holds supplier records for Latanoprostene Bunod? 6 organisations hold a current record for Latanoprostene Bunod: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: Taiwan (2), Czechia (1), India (1) and Italy (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Latanoprostene Bunod: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/latanoprostene-bunod

Reading the evidence

  • 6 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 3 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Latanoprostene Bunod expires 21 Feb 2029. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (6)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Latanoprostene Bunod. Country is the organisation's recorded country, not necessarily the manufacturing site.

Taiwan2Czechia1India1Italy1Country not recorded for 1
Need Latanoprostene Bunod sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (2 listed products contain Latanoprostene Bunod). The latest listed patent expires 21 Feb 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Latanoprostene bunod is a prostaglandin analog used topically in the management of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is a nitric oxide-donating prodrug of latanoprost, which primarily works by remodeling the trabecular meshwork to enhance aqueous humor outflow.

Chemical identity

IUPAC name
4-nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
Canonical SMILES
C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O
InChIKey
LOVMMUBRQUFEAH-UIEAZXIASA-N
Synonyms
Vyzulta API, bol-303259-x, ncx-116, ncx116, pf-3187207, vyzulta

Therapeutic areas

Ophthalmology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Latanoprostene Bunod?

6 organisations hold an active US FDA Type II Drug Master File or a CEP for Latanoprostene Bunod: CAYMAN PHARMA SRO (Czechia), CHIROGATE INTERNATIONAL INC (Taiwan), EVERLIGHT CHEMICAL INDUSTRIAL CORP (Taiwan), MSN Laboratories Private Limited (India), NEWCHEM SPA (Italy) and YS LIFE SCIENCE CO LTD. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Latanoprostene Bunod Drug Master Files are active?

CAYMAN PHARMA SRO (DMF 37429), CHIROGATE INTERNATIONAL INC (DMF 37976), EVERLIGHT CHEMICAL INDUSTRIAL CORP (DMF 39153), MSN Laboratories Private Limited (DMF 34033), NEWCHEM SPA (DMF 42791) and YS LIFE SCIENCE CO LTD (DMF 40478). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does the FDA Orange Book list patents for products containing Latanoprostene Bunod?

Yes. The latest patent listed for an approved US product containing Latanoprostene Bunod expires 21 Feb 2029, across 2 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Latanoprostene Bunod supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Latanoprostene Bunod?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.